Veru Initiates Phase 2b Clinical Trial for Obesity Drug Enobosarm
- Trial Launch: Veru plans to initiate the Phase 2b PLATEAU clinical trial in Q1 2026 to evaluate the effects of enobosarm in combination with semaglutide on older patients with obesity, potentially offering a new solution for obesity treatment.
- Improved Financials: In Q1 FY2026, Veru's R&D expenses decreased to $1.3 million from $5.7 million year-over-year, demonstrating effective cost control, while operating losses were reduced from $10.2 million to $5.4 million, indicating an improvement in the company's financial health.
- Positive FDA Feedback: The company received clear regulatory guidance from the FDA in September 2025 regarding the development pathways for enobosarm in combination with GLP-1 RA, confirming that a 3mg dosage of enobosarm is suitable for future clinical development, paving the way for potential drug approval.
- Research Presentation: Veru showcased positive results from the Phase 2b QUALITY trial at the ObesityWeek conference in November 2025, indicating that enobosarm can promote fat loss while preserving muscle mass, providing a higher quality weight loss solution for patients with obesity.
Trade with 70% Backtested Accuracy
Analyst Views on VERU
About VERU
About the author
Veru Inc. Q1 2026 Earnings Call Insights
- Clinical Pipeline Advancement: Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs, enobosarm in combination with GLP-1 receptor agonists, aimed at improving weight loss outcomes in obese patients, particularly older individuals, demonstrating potential in preserving lean mass and physical function.
- Regulatory Clarity from FDA: Steiner noted two potential approval pathways for the enobosarm/GLP-1 combination during a recent FDA meeting, either achieving at least a 5% placebo-corrected weight loss at 52 weeks or demonstrating clinically meaningful benefits in physical function with less than 5% weight loss, indicating the company's regulatory clarity.
- Improved Financial Position: CFO Greco reported net proceeds of approximately $23.4 million, with R&D costs decreasing from $5.7 million to $1.3 million primarily due to the wind-down of the QUALITY study, showcasing effective cost control and enhanced cash flow.
- Future Outlook: Management expects the PLATEAU study to commence this quarter, targeting interim results in Q1 2027, emphasizing confidence in clinical trial design and regulatory strategy, despite ongoing challenges with profitability.
Veru Reports Q1 2025 Earnings with Significant Cash Increase
- Earnings Beat: Veru's Q1 2025 GAAP EPS of -$0.26 surpassed expectations by $0.21, indicating an improvement in financial performance that may bolster investor confidence moving forward.
- Cash Position Strengthened: As of December 31, 2025, the company reported cash, cash equivalents, and restricted cash totaling $33.0 million, a significant increase from $15.8 million as of September 30, 2025, enhancing liquidity for future R&D and operations.
- Positive Stock Reaction: Following the earnings release, Veru's shares rose by 5%, reflecting market recognition of the company's financial health and potentially attracting more investor interest in its future developments.
- R&D Advancements: Veru is conducting a 72-week Phase IIb PLATEAU study targeting the obesity plateau population, adhering to FDA guidance, which demonstrates the company's ongoing commitment to innovative drug development and may lay the groundwork for future revenue growth.
Veru Initiates Phase 2b Clinical Trial for Obesity Drug Enobosarm
- Trial Launch: Veru plans to initiate the Phase 2b PLATEAU clinical trial in Q1 2026 to evaluate the effects of enobosarm in combination with semaglutide on older patients with obesity, potentially offering a new solution for obesity treatment.
- Improved Financials: In Q1 FY2026, Veru's R&D expenses decreased to $1.3 million from $5.7 million year-over-year, demonstrating effective cost control, while operating losses were reduced from $10.2 million to $5.4 million, indicating an improvement in the company's financial health.
- Positive FDA Feedback: The company received clear regulatory guidance from the FDA in September 2025 regarding the development pathways for enobosarm in combination with GLP-1 RA, confirming that a 3mg dosage of enobosarm is suitable for future clinical development, paving the way for potential drug approval.
- Research Presentation: Veru showcased positive results from the Phase 2b QUALITY trial at the ObesityWeek conference in November 2025, indicating that enobosarm can promote fat loss while preserving muscle mass, providing a higher quality weight loss solution for patients with obesity.
Veru Scheduled to Announce Q1 Earnings on February 11
- Earnings Announcement: Veru is set to announce its Q1 2023 earnings on February 11 before market open, with a consensus EPS estimate of -$0.47, indicating challenges in profitability.
- Earnings Estimate Changes: Over the last three months, Veru's EPS estimates have seen no upward revisions and one downward revision, reflecting analysts' diminishing confidence in the company's future earnings potential, which may impact investor sentiment.
- Clinical Study Progress: Veru is conducting a 72-week Phase IIb PLATEAU study targeting the obesity plateau population, following FDA guidance, which could support the company's future product pipeline and market positioning.
- Historical Financial Data: Veru's historical financial data and analyst ratings indicate volatility in the company's market performance, prompting investors to closely monitor the upcoming earnings report to assess future growth potential.
Veru details 72-week Phase IIb PLATEAU study aimed at obesity plateau group in accordance with FDA recommendations.
Management Transition: Veru Inc. has shifted to focus solely on drug development in cardiometabolic and inflammatory diseases, highlighted by the introduction of enobosarm and sabizabulin, following the sale of its FC2 Female Condom business.
Clinical Trial Updates: The completion of the Phase IIb QUALITY trial showed promising results for enobosarm in preserving lean mass and enhancing fat loss when combined with GLP-1 receptor agonists, leading to the launch of a new 72-week Phase IIb PLATEAU trial targeting obesity in older patients.
Financial Performance: Veru reported a net loss of $15.7 million for fiscal 2025, with increased R&D expenses, but also completed a public offering that bolstered its cash position to support upcoming trials.
Regulatory and Strategic Outlook: Management expressed confidence in navigating regulatory pathways for enobosarm, emphasizing the importance of clinical results and financial readiness, while acknowledging the need for additional capital to sustain operations beyond the interim analysis of the PLATEAU study.
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
Veru Inc. Q1 2026 Earnings Call Insights
- Clinical Pipeline Advancement: Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs, enobosarm in combination with GLP-1 receptor agonists, aimed at improving weight loss outcomes in obese patients, particularly older individuals, demonstrating potential in preserving lean mass and physical function.
- Regulatory Clarity from FDA: Steiner noted two potential approval pathways for the enobosarm/GLP-1 combination during a recent FDA meeting, either achieving at least a 5% placebo-corrected weight loss at 52 weeks or demonstrating clinically meaningful benefits in physical function with less than 5% weight loss, indicating the company's regulatory clarity.
- Improved Financial Position: CFO Greco reported net proceeds of approximately $23.4 million, with R&D costs decreasing from $5.7 million to $1.3 million primarily due to the wind-down of the QUALITY study, showcasing effective cost control and enhanced cash flow.
- Future Outlook: Management expects the PLATEAU study to commence this quarter, targeting interim results in Q1 2027, emphasizing confidence in clinical trial design and regulatory strategy, despite ongoing challenges with profitability.
Veru Reports Q1 2025 Earnings with Significant Cash Increase
- Earnings Beat: Veru's Q1 2025 GAAP EPS of -$0.26 surpassed expectations by $0.21, indicating an improvement in financial performance that may bolster investor confidence moving forward.
- Cash Position Strengthened: As of December 31, 2025, the company reported cash, cash equivalents, and restricted cash totaling $33.0 million, a significant increase from $15.8 million as of September 30, 2025, enhancing liquidity for future R&D and operations.
- Positive Stock Reaction: Following the earnings release, Veru's shares rose by 5%, reflecting market recognition of the company's financial health and potentially attracting more investor interest in its future developments.
- R&D Advancements: Veru is conducting a 72-week Phase IIb PLATEAU study targeting the obesity plateau population, adhering to FDA guidance, which demonstrates the company's ongoing commitment to innovative drug development and may lay the groundwork for future revenue growth.
Veru Initiates Phase 2b Clinical Trial for Obesity Drug Enobosarm
- Trial Launch: Veru plans to initiate the Phase 2b PLATEAU clinical trial in Q1 2026 to evaluate the effects of enobosarm in combination with semaglutide on older patients with obesity, potentially offering a new solution for obesity treatment.
- Improved Financials: In Q1 FY2026, Veru's R&D expenses decreased to $1.3 million from $5.7 million year-over-year, demonstrating effective cost control, while operating losses were reduced from $10.2 million to $5.4 million, indicating an improvement in the company's financial health.
- Positive FDA Feedback: The company received clear regulatory guidance from the FDA in September 2025 regarding the development pathways for enobosarm in combination with GLP-1 RA, confirming that a 3mg dosage of enobosarm is suitable for future clinical development, paving the way for potential drug approval.
- Research Presentation: Veru showcased positive results from the Phase 2b QUALITY trial at the ObesityWeek conference in November 2025, indicating that enobosarm can promote fat loss while preserving muscle mass, providing a higher quality weight loss solution for patients with obesity.
Veru Scheduled to Announce Q1 Earnings on February 11
- Earnings Announcement: Veru is set to announce its Q1 2023 earnings on February 11 before market open, with a consensus EPS estimate of -$0.47, indicating challenges in profitability.
- Earnings Estimate Changes: Over the last three months, Veru's EPS estimates have seen no upward revisions and one downward revision, reflecting analysts' diminishing confidence in the company's future earnings potential, which may impact investor sentiment.
- Clinical Study Progress: Veru is conducting a 72-week Phase IIb PLATEAU study targeting the obesity plateau population, following FDA guidance, which could support the company's future product pipeline and market positioning.
- Historical Financial Data: Veru's historical financial data and analyst ratings indicate volatility in the company's market performance, prompting investors to closely monitor the upcoming earnings report to assess future growth potential.
Veru details 72-week Phase IIb PLATEAU study aimed at obesity plateau group in accordance with FDA recommendations.
Management Transition: Veru Inc. has shifted to focus solely on drug development in cardiometabolic and inflammatory diseases, highlighted by the introduction of enobosarm and sabizabulin, following the sale of its FC2 Female Condom business.
Clinical Trial Updates: The completion of the Phase IIb QUALITY trial showed promising results for enobosarm in preserving lean mass and enhancing fat loss when combined with GLP-1 receptor agonists, leading to the launch of a new 72-week Phase IIb PLATEAU trial targeting obesity in older patients.
Financial Performance: Veru reported a net loss of $15.7 million for fiscal 2025, with increased R&D expenses, but also completed a public offering that bolstered its cash position to support upcoming trials.
Regulatory and Strategic Outlook: Management expressed confidence in navigating regulatory pathways for enobosarm, emphasizing the importance of clinical results and financial readiness, while acknowledging the need for additional capital to sustain operations beyond the interim analysis of the PLATEAU study.
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
